Takuji Okusaka

Research interests

Publications

• Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study

  ˜The œLancet. Gastroenterology & hepatology · 2024 · https://doi.org/10.1016/s2468-1253(24)00095-5

• Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

  NEJM Evidence · 2022 · https://doi.org/10.1056/evidoa2200015

• JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

  Journal of Gastroenterology · 2021 · https://doi.org/10.1007/s00535-021-01827-7

• Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition

  Journal of Hepato-Biliary-Pancreatic Sciences · 2020 · https://doi.org/10.1002/jhbp.870

• Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00808

• Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

  Gut · 2019 · 10.1136/gutjnl-2019-318934

• Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(18)30937-9

• Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer

  Nature Genetics · 2016 · https://doi.org/10.1038/ng.3547

• Genomic spectra of biliary tract cancer

  Nature Genetics · 2015 · https://doi.org/10.1038/ng.3375

• A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

  Annals of Oncology · 2015 · https://doi.org/10.1093/annonc/mdv027

• Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00050-9

• Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition

  Journal of Hepato-Biliary-Pancreatic Sciences · 2015 · https://doi.org/10.1002/jhbp.233

• Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

  Nature Genetics · 2014 · https://doi.org/10.1038/ng.3126

• Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.43.3680

• Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators

  Nature Genetics · 2012 · https://doi.org/10.1038/ng.2291

• Everolimus for Advanced Pancreatic Neuroendocrine Tumors

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1009290

• Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

  British Journal of Cancer · 2010 · https://doi.org/10.1038/sj.bjc.6605779

• A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

  British Journal of Cancer · 2007 · https://doi.org/10.1038/sj.bjc.6603855

• Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

  British Journal of Cancer · 2004 · https://doi.org/10.1038/sj.bjc.6602204

Current projects

No projects listed.